Intracellular interleukin-1 receptor antagonist and uses thereof
View Patent ↗Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over-expression of intracellular isoform of IL-1 receptor antagonist confers to recipient cells resistance to signaling pathways of proinflammatory cytokines (such as tumor necrosis factor alpha and IL-1 beta) that induce matrix metalloproteinase and subsequent tissue degradation. Hence, over-expression of intracellular IL-1 receptor antagonist may inhibit tissue destruction in various inflammatory disorders such as rheumatoid arthritis, other arthritides, degenerative intervertebral disc disease and chronic skin ulcers that occurs in diabetes mellitus and bed-ridden patients.
1. A method of inhibiting tissue degradation, comprising
contacting a collagenase-producing cell in a tissue with an intracellular IL-1 receptor antagonist peptide(s) selected from the group consisting of SEQ ID NOs: 13, 23, and 24; and
inhibiting the expression of collagenase via said contact, thereby inhibiting tissue degradation.
2. The method of claim 1 , wherein said tissue degradation is a component of chronic inflammatory disorder, wherein said chronic inflammatory disorder is arthritis, degenerative intervertebral disc disease or chronic skin ulcers.
3. A method of treating a chronic inflammatory disorder in a individual, comprising the step of administering an intracellular IL-1 receptor antagonist peptide(s) selected from the group consisting of SEQ ID NO: 13, 23, and 24 to the tissue of said individual, wherein the administration of said antagonist inhibits degradation of said tissue through inhibiting the expression of a collagenase.
4. The method of claim 3 , wherein said chronic inflammatory disorder is selected from the group consisting of arthritis, degenerative intervertebral disc disease and chronic skin ulcers.